Symphony Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Symphony Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-49,602	Closed	-$1.47M	–	52
2020 Q1	$1.47M	Buy	+49,602	New	+$1.68M	0.46%	33
2017 Q2	–	Sell	-11,404	Closed	-$168K	–	407
2017 Q1	$168K	Sell	11,404 -194	-2%	-$3.14K	0.02%	383
2016 Q4	$187K	Buy	+11,598	New	+$210K	0.02%	389

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Symphony Asset Management's HZNP Position: Q2 2020 in Review

Symphony Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2020, closing a stake of 49,602 shares — an estimated $1.47M sold.

Symphony Asset Management first reported a position in HZNP in Q4 2016 and held it in 3 quarters. The position peaked at $1.47M in Q1 2020. 354 funds tracked by Wall St. Rank hold HZNP as of Q2 2020.

Symphony Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2020 after selling out during the quarter.
Symphony Asset Management sold 49,602 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2020, an estimated $1.47M.
Symphony Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2016 and held it in 3 quarters.
Symphony Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.47M in Q1 2020.
354 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2020.

Based on Symphony Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.